FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2602457837> ?p ?o ?g. }

• W2602457837 abstract "5122 Background: EBRT with ADT (4 mos to 2–3 yrs) is standard treatment for high risk PC. In this trial, we evaluated weekly P given concurrently with EBRT and ADT in high risk PC. Methods: For pts undergoing RP, high risk was defined as: pT3 and/or pN+, M0, and/or rising PSA (> 0.5) post RP. For pts not undergoing RP (i.e. locally advanced PC [LAPC]) high risk included: cT2b-4N0, N+, M0; bGS 8–10; bGS ≥ 7 + PSA ≥ 10 but ≤ 150; and/or PSA ≥ 20 but ≤ 150. Treatment included ADT (4 or 24 mos, preplanned based on clinical presentation), P (40, 50, or 60 mg/m2/wk) x 7 with EBRT, and whole pelvis EBRT 45 Gy with 19.8 Gy boost (total 64.8 Gy) to prostate bed in RP pts and 25.2 Gy boost (total 70.2 Gy) to prostate in LAPC pts. Results: Between October 1999 and December 2006, 59 pts (29 W, 28 AA) were enrolled (n = 29 LAPC, n = 30 RP); median age 67 yrs, median PSA at trial entry 5.9 (27.5 LAPC, 1.6 RP), median GS 8. Pts were enrolled at different weekly doses of P: 40 mg/m2 n = 10 pts; 50 mg/m2 n = 31 pts; 60 mg/m2 n = 18 pts. ADT for 4 mos was given in 29 pts and for 24 mos in 30 pts. At 40 mg/m2 67/70 (96%), 50 mg/m2 202/217 (93%), and 60 mg/m2 98/126 (78%) planned doses of P were given. There were no acute grade 4 toxicities. Most common grade 3 toxicities were diarrhea 15%, urinary urgency or incontinence 10%, tenesmus 5%, and leukopenia 3%. Median duration of f/u was 75.3 mos, OS 78%, biochemical progression 24/59 (41%) pts, clinical progression 11/59 (19%) pts. Time to biochemical progression was similar between RP vs. LAPC (p = 0.17), between ADT 4 mos vs. 24 mos (p = 0.61), and between AA vs. W (p = 0.54). Conclusions: This trial establishes the feasibility of tri-modality therapy with ADT, EBRT and weekly paclitaxel in high risk PC, both in RP pts and in LAPC pts with intact prostate glands. The maximum tolerated dose of paclitaxel is 50 mg/m2 /wk when given weekly with concurrent radiation to the pelvis and hormone ablation. No significant financial relationships to disclose." @default.
• W2602457837 created "2017-04-07" @default.
• W2602457837 creator A5004217393 @default.
• W2602457837 creator A5012068082 @default.
• W2602457837 creator A5013607216 @default.
• W2602457837 creator A5026179839 @default.
• W2602457837 creator A5052573263 @default.
• W2602457837 creator A5052972613 @default.
• W2602457837 creator A5076668339 @default.
• W2602457837 creator A5083325270 @default.
• W2602457837 date "2009-05-20" @default.
• W2602457837 modified "2023-10-16" @default.
• W2602457837 title "Weekly paclitaxel (P) with concurrent external beam radiation (EBRT) and androgen deprivation therapy (ADT) in high-risk prostate cancer (PC) patients with or without prior prostatectomy (RP)" @default.
• W2602457837 doi "https://doi.org/10.1200/jco.2009.27.15_suppl.5122" @default.
• W2602457837 hasPublicationYear "2009" @default.
• W2602457837 type Work @default.
• W2602457837 sameAs 2602457837 @default.
• W2602457837 citedByCount "0" @default.
• W2602457837 crossrefType "journal-article" @default.
• W2602457837 hasAuthorship W2602457837A5004217393 @default.
• W2602457837 hasAuthorship W2602457837A5012068082 @default.
• W2602457837 hasAuthorship W2602457837A5013607216 @default.
• W2602457837 hasAuthorship W2602457837A5026179839 @default.
• W2602457837 hasAuthorship W2602457837A5052573263 @default.
• W2602457837 hasAuthorship W2602457837A5052972613 @default.
• W2602457837 hasAuthorship W2602457837A5076668339 @default.
• W2602457837 hasAuthorship W2602457837A5083325270 @default.
• W2602457837 hasConcept C121608353 @default.
• W2602457837 hasConcept C126322002 @default.
• W2602457837 hasConcept C126894567 @default.
• W2602457837 hasConcept C2775908122 @default.
• W2602457837 hasConcept C2777899217 @default.
• W2602457837 hasConcept C2779466945 @default.
• W2602457837 hasConcept C2780192828 @default.
• W2602457837 hasConcept C29456083 @default.
• W2602457837 hasConcept C2989005 @default.
• W2602457837 hasConcept C71924100 @default.
• W2602457837 hasConceptScore W2602457837C121608353 @default.
• W2602457837 hasConceptScore W2602457837C126322002 @default.
• W2602457837 hasConceptScore W2602457837C126894567 @default.
• W2602457837 hasConceptScore W2602457837C2775908122 @default.
• W2602457837 hasConceptScore W2602457837C2777899217 @default.
• W2602457837 hasConceptScore W2602457837C2779466945 @default.
• W2602457837 hasConceptScore W2602457837C2780192828 @default.
• W2602457837 hasConceptScore W2602457837C29456083 @default.
• W2602457837 hasConceptScore W2602457837C2989005 @default.
• W2602457837 hasConceptScore W2602457837C71924100 @default.
• W2602457837 hasLocation W26024578371 @default.
• W2602457837 hasOpenAccess W2602457837 @default.
• W2602457837 hasPrimaryLocation W26024578371 @default.
• W2602457837 hasRelatedWork W1972121220 @default.
• W2602457837 hasRelatedWork W1998796379 @default.
• W2602457837 hasRelatedWork W2015607464 @default.
• W2602457837 hasRelatedWork W2118670275 @default.
• W2602457837 hasRelatedWork W2402249956 @default.
• W2602457837 hasRelatedWork W2545489389 @default.
• W2602457837 hasRelatedWork W2909802736 @default.
• W2602457837 hasRelatedWork W3122531660 @default.
• W2602457837 hasRelatedWork W4319748405 @default.
• W2602457837 hasRelatedWork W193188344 @default.
• W2602457837 isParatext "false" @default.
• W2602457837 isRetracted "false" @default.
• W2602457837 magId "2602457837" @default.
• W2602457837 workType "article" @default.